Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New risk score could tailor therapy for aggressive myeloma

NCT ID NCT07045168

Disease control Sponsor: FengYan Jin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study aims to personalize treatment for people newly diagnosed with multiple myeloma who have an extra copy of chromosome 1q, a marker of higher risk. Researchers will use a scoring system based on factors like disease stage and lab results to classify patients into low, intermediate, or high-risk groups. Each group will then receive a tailored treatment plan, with the goal of improving how well the cancer responds and reducing the chance of it coming back.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
risk-scoring model (a tool to classify patients into risk groups based on clinical features, guiding treatment intensity)
What this could lead to
If successful, this could lead to more personalized and effective treatment plans for multiple myeloma patients with +1q, potentially improving survival and reducing side effects.
What could go wrong
This is an early-stage, non-randomized study with 200 participants, so results may not apply to all patients. The risk model may not accurately predict outcomes, and individual responses to treatment can vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Newly diagnosed NDMM by 2014 IMWG criteria

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>=18, or \>=65 and fit according to IMWG-FI. * Newly diagnosed NDMM by 2014 IMWG criteria. * Adequate organ function for systemic therapy. * Signed informed consent. Exclusion Criteria: * Active infections requiring systemic treatment. * Unstable angina, NYHA class III-IV heart failure, or uncontrolled arrhythmias. * History of hematologic or solid tumors treated with chemo/radiotherapy within 5 years. * Current malignancies requiring therapy. * Refusal to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Neoplasm, Residual plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.